Sutro Biopharma, Inc. (STRO)
Stock Price:
$7.44 USD
-0.33 (-4.25%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
266.93M |
| Revenue (ttm) |
41.26M |
| Net Income (ttm) |
-61.09M |
| Shares Out |
35.88M |
| EPS (ttm) |
-2.65 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$7.44 |
| Previous Close |
$7.77 |
| Change ($) |
-0.33 |
| Change (%) |
-4.25% |
| Day's Open |
7.93 |
| Day's Range |
7.33 - 7.95 |
| Day's Volume |
302,035 |
| 52-Week Range |
6.00 - 12.75 |
More Stats
| Market Cap |
266.93M |
| Enterprise Value |
175.68M |
| Earnings Date (est) |
Aug 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
35.88M |
| Float |
14.84M |
| EPS (basic) |
-2.64 |
| EPS (diluted) |
-2.65 |
| FCF / Share |
-2.91 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
129,204 |
| Short Ratio |
1.22 |
| Short % of Float |
0.42% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
6.47 |
| PB Ratio |
3.61 |
| Revenue |
41.26M |
| Operating Income |
-60.38M |
| Net Income |
-61.09M |
| Free Cash Flow |
-67.58M |
| Net Cash |
91.25M |
| Net Cash / Share |
2.54 |
| Gross Margin |
-55.44% |
| Operating Margin |
-146.35% |
| Profit Margin |
-148.10% |
| FCF Margin |
-163.79% |
| ROA |
-21.30% |
| ROE |
-57.41% |
| ROIC |
-44.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (7)
| Buy |
7 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$18.50*
(148.66% upside)
Low
16.0
Current: 7.44
High
20.0
Target: 18.50
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 42.74 | 38.42 | 51.74 | 59.73 |
| Revenue Growth | 11.24% | -25.75% | -13.38% | - |
| Gross Profit | 42.74 | 38.42 | 51.74 | 59.73 |
| Operating Income | -55.47 | -37.22 | -19.27 | 1.36 |
| Net Income | -55.74 | -35.32 | -19.69 | 1.70 |
| Shares Outstanding | 22.96 | 5.76 | 0.45 | 0.41 |
| Earnings Per Share | -2.43 | -6.13 | -43.95 | - |
| Operating Cash Flow | -65.02 | 12.68 | -37.07 | -13.15 |
| Capital Expenditures | -3.48 | -1.56 | -3.32 | -4.38 |
| Free Cash Flow | -68.50 | 11.13 | -40.39 | -17.53 |
| Cash & Equivalents | 118 | 205 | 22.04 | 47.80 |
| Total Debt | 9.88 | 14.72 | 14.56 | - |
| Net Cash / Debt | 108 | 190 | 7.47 | 47.80 |
| Assets | 156 | 223 | 40.77 | 69.28 |
| Liabilities | 58.58 | 91.60 | 47.27 | 57.67 |
| Book Value | 97.79 | 132 | -109 | -90.90 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Sutro Biopharma, Inc. |
| Country |
United States |
| Employees |
177 |
| CEO |
William J. Newell |
Stock Information
| Ticker Symbol |
STRO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: STRO |
| IPO Date |
September 27, 2018 |
Description
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.